Atacand 8 mg - 28 Tablet

-Chronic hypertension: Oral: Initial: 8 mg once daily; evaluate response after approximately 2 to 4 weeks and titrate dose (eg, increase the daily dose by doubling), as needed, up to 32 mg once daily; if additional blood pressure control is needed, consider combination therapy. Patients with severe asymptomatic hypertension and no signs of acute end organ damage should be evaluated for medication titration within 1 week. -Acute coronary syndromes:1-Non-ST-elevation acute coronary syndrome: Oral: Initial: 8 mg once daily; increase dose as tolerated up to 32 mg/day under close monitoring to avoid hypotension. 2-ST-elevation myocardial infarction: Oral: Initial: 8 mg once daily; increase dose as tolerated up to 32 mg/day under close monitoring to avoid hypotension. -Heart failure with reduced ejection fraction: Oral: Initial: 4 to 8 mg once daily; increase dose (eg, double) every ≥2 weeks based on response and tolerability to a target dose of 32 mg once daily. -Proteinuric chronic kidney disease: Oral: Initial: 8 mg once daily; can be increased to 32 mg once daily based on blood pressure response and tolerability. Target to an appropriate blood pressure goal and a proteinuria goal of <1 g/day. -Pediatric dosing: Hypertension: A-In case of children 1 to <6 years: Oral: Initial: 0.2 mg/kg/day once daily; titrate to response (within 2 weeks, antihypertensive effect usually observed); usual range: 0.05 to 0.4 mg/kg/day divided once or twice daily; maximum daily dose: 0.4 mg/kg/day. -For the rest of pediatric dosing refer to Dosage and Administration.